
Oct 1, 2023
∙ Paid

Papers reviewed:
- 2023 Sep.23 – Man-Yuan Li et al – Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
- 2023 May – Samy et al – Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
- 2022 Nov – Lotfalizadeh et al – The Anticancer potential of Ivermectin: Mechanisms of action and therapeutic implications
- 2022 Oct – Jian Liu et al – Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
- 2022 Jun – Daeun Lee et al – Ivermectin suppresses pancreatic cancer via mitochondria dysfunction
- 2021 Aug – Shican Zhou et al – Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
- 2021 Jan – Mingyang Tang et al – Ivermectin, a potential anticancer drug derived from an antiparasitic drug
- 2019 Sep Intuyod et al – Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro
- “2018 Feb – Juarez et al – The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug 2018 Feb – Juarez et al – The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug”
Leave a Reply